BioPharma Resources

Drug Trial Radar · NCT07662811

SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer

SYHX2011 in Combination With Carboplatin and Enlonstobart Versus Nab-Paclitaxel Plus Carboplatin and Tislelizumab as First-Line Therapy for Squamous Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Phase II/III Study

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

396

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Shanghai Chest HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • SYHX2011Drug

    SYHX2011:260 mg/m\^2, IV/30 ± 3 minutes(day1)

  • CarboplatinDrug

    Carboplatin: AUC 5 mg/mL/min, IV/30\~60 minutes(day1)

  • EnlonstobartDrug

    Enlonstobart: 360 mg, IV/60 minutes(day1)

  • Nab-PaclitaxelDrug

    Nab-Paclitaxel: 260 mg/m\^2, IV/30 ± 3 minutes(day1)

  • CarboplatinDrug

    Carboplatin: AUC 5 mg/mL/min, IV/30\~60 minutes(day1)

  • TislelizumabDrug

    Tislelizumab: 200 mg, IV/60 minutes(day1)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) for phase IITime frame: Throughout the study period, an average of 3 years
  2. Progression Free Survival (PFS) for phase IIITime frame: Throughout the study period, an average of 3 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.